Want to see AU:NSB full AI Analyst Report?
NSB Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.26
Previous CloseN/A
Volume70.60K
Average Volume (3M)306.60K
Market Cap
AU$23.77M
Enterprise ValueAU$19.56M
Total Cash (Recent Filing)AU$6.36M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding389,718,540
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA reported zero-debt capital structure removes interest obligations and materially reduces refinancing risk. For an R&D-intensive biotech, being debt-free provides durable financial flexibility to fund trials or negotiate partnerships without the immediate pressure of debt-servicing constraints.
Positive Equity BaseSustained positive equity and equity-funded assets give the company the capacity to absorb losses and continue investing in development programs. This balance-sheet resilience supports strategic options like licensing, collaborations, or staged financing over the medium term.
Lean Operating FootprintA nine-person workforce signals a lean cost structure and lower fixed overhead. Structurally, a small team can extend cash runway per funding dollar, enable nimble project prioritization, and limit structural burn compared with larger peers in the development phase.
Bears Say
Revenue CollapseAnnual revenue falling to zero in 2025 after prior declines indicates a loss of commercial traction or contract/license revenue. Over the medium term this erodes the company’s ability to self-fund development and raises the bar for securing non-dilutive or partnership revenue streams.
Persistent Negative Cash FlowRepeated negative operating and free cash flows, with a sharp 2025 deterioration, imply structural cash burn. This creates ongoing funding dependence, increasing the likelihood of dilution, deal-dependent financing, or constrained program execution without new capital sources.
Recurring Operating LossesSustained operating losses and a reversion to net loss in 2025 show inconsistent profitability and negative returns on equity. Structurally, this undermines long-term shareholder value unless the company achieves durable revenue or successful asset exits.
Neuroscientific Biopharmaceuticals Ltd. News
NSB FAQ
What was Neuroscientific Biopharmaceuticals Ltd.’s price range in the past 12 months?
Neuroscientific Biopharmaceuticals Ltd. lowest share price was AU$0.06 and its highest was AU$0.26 in the past 12 months.
What is Neuroscientific Biopharmaceuticals Ltd.’s market cap?
Neuroscientific Biopharmaceuticals Ltd.’s market cap is AU$23.77M.
When is Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date?
Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 39 days.
How were Neuroscientific Biopharmaceuticals Ltd.’s earnings last quarter?
Neuroscientific Biopharmaceuticals Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Neuroscientific Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Neuroscientific Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Neuroscientific Biopharmaceuticals Ltd. pay dividends?
Neuroscientific Biopharmaceuticals Ltd. does not currently pay dividends.
What is Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate?
Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuroscientific Biopharmaceuticals Ltd. have?
Neuroscientific Biopharmaceuticals Ltd. has 389,718,540 shares outstanding.
What happened to Neuroscientific Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Neuroscientific Biopharmaceuticals Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neuroscientific Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:NSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuroscientific Biopharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
265.85%
12-Months-Change
Fundamentals
Return on Equity
-19.10%
Trailing 12-Months
Asset Growth
232.64%
Trailing 12-Months
Company Description
Neuroscientific Biopharmaceuticals Ltd.
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Technical Analysis
Actinogen Medical
―
Neuren Pharmaceuticals Limited
―
Alterity Therapeutics
―
Zelira Therapeutics
―
PYC Therapeutics Limited
―